Daniel Rodriguez-Granrose, Ph.D., PSM

Daniel brings 11 years of biopharma and cell therapy industry experience to DHC. This experience includes successful transfer of multiple therapeutics into GMP manufacturing as process lead, commercial scale up of cell and viral cultures, serum-free media development, use of DOE for process optimization, and management of large cross-functional teams though each stage of bioprocess and CMC development.

Before joining DHC, Daniel worked as Senior Manager/Senior Scientist for DiscGenics Inc, where he led the Chemistry Manufacturing and Controls and Bioprocess Development teams. In this role Daniel devised and formally directed the company’s Quality by Design (QbD) efforts including the scientific rationale, bioprocess establishment and execution, regulatory considerations, and coordination between functional groups. Through use of multi-donor experimental design and analysis Daniel’s team built a true in multi-donor allogeneic cell therapy design space. Daniel’s group used this design space and computational fluid dynamics to scale their cell sphere bioprocess into 50L stirred tank reactors while maintaining critical quality attributes.

While at Sanofi Inc., Daniel led bioprocess development for 9 unique projects including the site’s highest priority project; he designed, operated, and optimized mammalian, insect, and viral processes from bench to industrial scale, ran 100s of bioreactors, and transferred successful processes from R&D to manufacturing.

Daniel received his PhD in Biochemistry and Molecular Biology from the University of Miami on the prestigious National Science Foundation Graduate Research Fellowship and his Professional Science Masters (a terminal biotechnology regulatory affairs and management degree) from the University of Georgia.